|
1
|
Pilliod RA, Feinberg BB and Burwick RM:
Maternal and Feto-placental phenotypes of early-onset severe
preeclampsia. J Matern Fetal Neonatal Med. 29:1209–1213.
2016.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Fisher SJ: Why is placentation abnormal in
preeclampsia? Am J Obstet Gynecol. 213 (4 Suppl):S115–S122.
2015.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Yang W, Wang A, Zhao C, Li Q, Pan Z, Han
X, Zhang C, Wang G, Ji C, Wang G, et al: miR-125b enhances IL-8
production in early-onset severe preeclampsia by targeting
Sphingosine-1-phosphate lyase 1. PLoS One.
11(e0166940)2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
van Esch JJA, van Heijst AF, de Haan AFJ
and van der Heijden OWH: Early-onset preeclampsia is associated
with perinatal mortality and severe neonatal morbidity. J Matern
Fetal Neonatal Med. 30:2789–2794. 2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
He Y, Xu B, Song D, Yu F, Chen Q and Zhao
M: Correlations between complement system's activation factors and
anti-angiogenesis factors in plasma of patients with
early/late-onset severe preeclampsia. Hypertens Pregnanc.
35:499–509. 2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Müller A, Horvat V, Vulin M, Mandić S,
Šerić V and Vidosavljević D: The soluble Fms-like tyrosin kinase-1
(sFLT-1) to placental growth factor (PIGF) ratio as a possible
indicator for the severity of preeclampsia-single institution
experience. Med Glas (Zenica). 16:53–59. 2019.PubMed/NCBI View
Article : Google Scholar
|
|
7
|
He Y, Xu B, Song D, Yu F, Chen Q and Zhao
M: Expression of the complement system's activation factors in
plasma of patients with early/late-onset severe pre-eclampsia. Am J
Reprod Immunol. 76:205–211. 2016.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Yusuf AM, Kahane A and Ray JG: First and
second trimester serum sFlt-1/PlGF ratio and subsequent
preeclampsia: A systematic review. J Obstet Gynaecol Can.
40:618–626. 2018.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Herraiz I, Simón E, Gómez-Arriaga P,
Martínez-Moratalla JM, García-Burguillo A, Jiménez EA and Galindo
A: Angiogenesis-related biomarkers (sFlt-1/PLGF) in the prediction
and diagnosis of placental dysfunction: An approach for clinical
integration. Int J Mol Sci. 16:19009–19026. 2015.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Suzuki H, Hirashima C, Nagayama S,
Takahashi K, Yamamoto T, Matsubara S and Ohkuchi A: Increased serum
levels of sFlt-1/PlGF ratio in preeclamptic women with onset at
<32 weeks compared with ≥32 weeks. Pregnancy Hypertens.
12:96–103. 2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Caillon H, Tardif C, Dumontet E, Winer N
and Masson D: Evaluation of sFlt-1/PlGF ratio for predicting and
improving clinical management of pre-eclampsia: Experience in a
specialized perinatal care center. Ann Lab Med. 38:95–101.
2018.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Yang K, Dong G, Tian Y and Li J: Effects
of compound Danshen injection combined with magnesium sulfate on
serum MPO and hs-CRP in patients with severe preeclampsia. Exp Ther
Med. 16:167–170. 2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Duley L, Gülmezoglu AM, Henderson-Smart DJ
and Chou D: Magnesium sulphate and other anticonvulsants for women
with Pre-eclampsia. Cochrane Database Syst Rev.
2010(CD000025)2010.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Bain ES, Middleton PF and Crowther CA:
Maternal adverse effects of different antenatal magnesium sulphate
regimens for improving maternal and infant outcomes: A systematic
review. BMC Pregnancy Childbirth. 13(195)2013.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Shekhar S, Sharma C, Thakur S and Verma S:
Oral nifedipine or intravenous labetalol for hypertensive emergency
in pregnancy: A randomized controlled trial. Obstet Gynecol.
122:1057–1063. 2013.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Duley L, Henderson-Smart DJ and Chou D:
Magnesium sulphate versus phenytoin for eclampsia. Cochrane
Database Syst Rev. (CD000128)2010.PubMed/NCBIdoi: 10.1002/14651858.CD000128.
|
|
17
|
Kassie GM, Negussie D and Ahmed JH:
Maternal outcomes of magnesium sulphate and diazepam use in women
with severe pre-eclampsia and eclampsia in Ethiopia. Pharm Pract
(Granada). 12(400)2014.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Giannubilo SR, Bezzeccheri V, Cecchi S,
Landi B, Battistoni GI, Vitali P, Cecchi L and Tranquilli AL:
Nifedipine versus labetalol in the treatment of hypertensive
disorders of pregnancy. Arch Gynecol Obstet. 286:637–642.
2012.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Abdel-Hady el-S, Fawzy M, El-Negeri M,
Nezar M, Ragab A and Helal AS: Is expectant management of
early-onset severe preeclampsia worthwhile in low-resource
settings? Arch Gynecol Obstet. 282:23–27. 2010.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Chen Q, Sousa JD, Snowise S, Chamley L and
Stone P: Reduction in the severity of early onset severe
preeclampsia during gestation may be associated with changes in
endothelial cell activation: A pathological case report. Hypertens
Pregnancy. 35:32–41. 2016.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Romero R, Chaemsaithong P, Tarca AL,
Korzeniewski SJ, Maymon E, Pacora P, Panaitescu B, Chaiyasit N,
Dong Z, Erez O, et al: Maternal plasma-soluble ST2 concentrations
are elevated prior to the development of early and late onset
preeclampsia-a longitudinal study. J Matern Fetal Neonatal Med.
31:418–432. 2018.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Wen J, Zhang X and Li C: Clinical effect
of low molecular weight heparin sodium combined with magnesium
sulfate in the treatment of patients with severe preeclampsia. J
Coll Physicians Surg Pak. 29:119–122. 2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Molvi SN, Mir S, Rana VS, Jabeen F and
Malik AR: Role of antihypertensive therapy in mild to moderate
pregnancy-induced hypertension: A prospective randomized study
comparing labetalol with alpha methyldopa. Arch Gynecol Obste.
285:1553–1562. 2012.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Das M, Chaudhuri PR, Mondal BC, Mitra S,
Bandyopadhyay D and Pramanik S: Assessment of serum magnesium
levels and its outcome in neonates of eclamptic mothers treated
with Low-dose magnesium sulfate regimen. Indian J Pharmacol.
47:502–508. 2015.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Sun CJ, Li L, Li XY, Zhang WY and Liu XW:
Associations of polymorphisms of CYP2D6 and CYP2C9 with early onset
severe pre-eclampsia and response to labetalol therapy. Arch
Gynecol Obstet. 298:125–132. 2018.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Abdelrahman TN, Youssry MA, Radwan AM and
Ahmed A: Impact of intravenous infusion of labetalol combined with
magnesium sulfate versus hydralazine combined with magnesium
sulfate on fetomaternal hemodynamics in severe preeclampsia. Ain
Shams J Anesthesiol. 11(5)2019.
|
|
27
|
Lu JF and Nightingale CH: Magnesium
sulfate in eclampsia and pre-eclampsia. Clin Pharmacokin.
38:305–314. 2000.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Xie RH, Guo Y, Krewski D, Mattison D,
Walker MC, Nerenberg K and Wen SW: Association between labetalol
use for hypertension in pregnancy and adverse infant outcomes. Eur
J Obstet Gynecol Reprod Biol. 175:124–128. 2014.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Foidart JM, Schaaps JP, Chantraine F,
Munaut C and Lorquet S: Dysregulation of anti-angiogenic agents
(sFlt-1, PLGF, and sEndoglin) in preeclampsia-a step forward but
not the definitive answer. J Reprod Immunol. 82:106–111.
2009.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Stepan H, Herraiz I, Schlembach D,
Verlohren S, Brennecke S, Chantraine F, Klein E, Lapaire O, Llurba
E, Ramoni A, et al: Implementation of the sFlt-1/PlGF ratio for
prediction and diagnosis of pre-eclampsia in singleton pregnancy:
Implications for clinical practice. Ultrasound Obstet Gynecol.
45:241–246. 2015.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Ohkuchi A, Hirashima C, Suzuki H,
Takahashi K, Yoshida M, Matsubara S and Suzuki M: Evaluation of a
new and automated electrochemiluminescence immunoassay for plasma
sFlt-1 and PlGF levels in women with preeclampsia. Hypertens Res.
33:422–427. 2010.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Schoofs K, Grittner U, Engels T, Pape J,
Denk B, Henrich W and Verlohren S: The importance of repeated
measurements of the sFlt-1/PlGF ratio for the prediction of
preeclampsia and intrauterine growth restriction. J Perinat Med.
42:61–68. 2014.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Xu B, Charlton F, Makris A and Hennessy A:
Antihypertensive drugs methyldopa, labetalol, hydralazine, and
clonidine improve trophoblast interaction with endothelial cellular
networks in vitro. J Hypertens. 32:1075–1083. 2014.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Xu B, Bobek G, Makris A and Hennessy A:
Antihypertensive methyldopa, labetalol, hydralazine, and clonidine
reversed tumour necrosis factor-α inhibited endothelial nitric
oxide synthase expression in Endothelial-trophoblast cellular
networks. Clin Exp Pharmacol Physiol. 44:421–427. 2017.PubMed/NCBI View Article : Google Scholar
|
